AKRIKHIN: COMPANY PRESENTATION

Transcription

1 AKRIKHIN: COMPANY PRESENTATION

2 AKRIKHIN OVERVIEW (1) Akrikhin at a glance Member of Polpharma Group Market position In ТОP 10 largest Russian manufacturers with a turnover more than $200 millions in 2013 Founded 19 October 1936 Product Portfolio More than 200 SKUs of key therapeutic classes (over 100 brands) Positioning Staff Socially important drugs for Russian healthcare (including ED, cardio, diabetes, tuberculosis) 1500 people History milestones Company foundation now Company was named after the drug Akrikhin for treatment of malaria that saved the country from the epidemics API period Production of more than 100 APIs - 24% of total production volume in the Soviet Union API export to 54 countries Production of finished pharmaceutical products New generic FDF Establishment Sales&Marketing Department International cooperation projects Member of Polpharma Group Expansion of product portfolio Excellence Sales&Marketing capabilities GMP introduction merge of Polpharma Sales&Marketing office with Akrikhin s one production technologies transfer R&D joint pipeline development access to best European practices and standards common training programmes for personnel Polpharma products share in Akrikhin revenue 36% Polpharma products

3 AKRIKHIN OVERVIEW (2) Key capabilities and strengths In depth: deep understanding of the workings of the Russian pharmaceutical market profound commercial capabilities, covering all routes to market channels Mission To benefit society by bringing affordable effective and high-quality medicines effective sales and marketing teams, covering all important target groups efficient FF team of more than 350 dedicated employees present in 70 cities across Russia modern production facilities meeting the standards of Good Manufacturing Practice (GMP) production of a vast range of drug forms research and development strong registration department experienced management team

4 Bln., roubles FINANCIAL RESULTS Akrikhin revenue dynamics +18% 6,8 +5% +19% 5,5 5,7 +20% 4,6 +19% 3,8 +42% 3,2 2, Akrikhin EBIT dynamics 19% 22% 22% 22% 23% 8% 0,10%

5 Source: Pharmaceutical bulletin, RNC Pharma, February 2014 Source: IMS, value Bln., roubles MARKET POSITION Market position 800,0 700,0 600,0 500,0 Akrikhin s 400,0 market 300,0 position 200,0 100,0 0,0 Market influence Total market ,6 241, , ,8 563,3 509,4 401, Akrikhin is in top-3 most recognized local companies of the Russian pharmaceutical market Local manufacturer 1 Pharmstandart 2 STADA 3 AKRIKHIN 4 Valenta 5 Ozon 6 Veropharm 7 KRKA-Rus 8 Evalar 9 Vertex 10 Sotex Sustained leadership in top-3 since 2010

6 SALES&MARKETING CAPABILITIES Annual FF headcount expansion Source: Akrikhin Established presence in Russia: about 400 people in 70 cities all across Russia Coverage in key therapeutical areas Specialization 2014 February, % Cardiology 29% Dermatology 32% Pediatrics 36% Gynecology 25% General Practitioners 18% Endocrinology 20% Rheumatology 35% Ophthalmology 18% Neurology 22% Pharmacies 34% Coverage of outpatient physicians is provided in cities where Akrikhin is presented Distribution channels 20,50% 79,50% Commerce Tender Source: Akrikhin, sales, rub., 2013

7 PRODUCTS CAPABILITIES Key therapeutical areas Wide product portfolio of more than 200 SKUs Cardiology Dermatology Pediatrics OTC Diabetes Tuberculosis Ophthalmology Urology Social focus Share of Essential Drugs in Company revenue Top 10 products Trade name Business segments Product category Share in revenue,% Capoten/Capozid Cardiology 1 13 Akriderm Dermatology 2 11 Aquadetrim Pediatrics 3 6 Glyformin Diabetes 4 5 Bystrumgel OTC 5 5 Normobact OTC 6 5 Trikhopol Gynecology 7 5 Phytolyzin Urology 8 4 Sopelka OTC 9 4 Acyclovir INN 10 4 Source: Akrikhin, 2013 Balanced presence in a wide and most rapidly growing market segments 55% 20% 13% 16% 51% Branded Generics OTC Tenders INN Source: Akrikhin Source: Akrikhin

8 R&D CAPABILITIES R&D activities Annual new products output up to 10 products Product development strategy concentrates on: - First generics - New combinations and dosages - New forms More than 70 products developed in More than 50 products in the pipeline R&D Center with more than 20 employees Pipeline development Pipeline distribution 41% In-license 59% Own-development More than 70 products launched in Strong network of partners for different types of codevelopments, both foreign researchers and Russian scientific research institutions Internal developments Joint R&D activities with Polpharma Cooperation projects

9 Source: Akrikhin PRODUCTION CAPABILITIES Facilities overview Location Staraya Kupavna 20 km from Moscow Main facilities 2 finishing dosage form facilities:1 for solids and 1 for soft form and liquids QC center R&D Pharma Labs FG&RM warehouse complex Custom Warehouse Pharmaceutical Warehouse Site Characteristics Total property 36 hectares Total industrial area 36 hectares Total manufacturing area m2 Facilities map Local manufacturing facilities with large capacity extension potential Production output (mln. packs) In 2013 Akrikhin production output was 59 mln. packs 5% 8% 13% 15% 57% Gels Ointments Tablets Suppositories Capsules Creams Syrups Shampoos

10 Source: Akrikhin, mln. packs INVESTMENT PROGRAMME IN PRODUCTION Programme objectives Production capacities growth To extend & to consolidate the production facilities, to increase their efficiency solid forms mln packs 56 60* To complete the modernization by GMP standards semi-solid forms mln packs * - further expandability possible The amount of investments in will reach 40 mln USD

11 QUALITY ASSURANCE Regulatory audits February, 2011: audit of ROSZDRAVNADZOR December, 2013: ISO certificate re-confirmation Positive clients audits April, 2013: audit of Bristol Myerrs Squibb July, 2013: audit of MSD

12